DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Batist G, Harris L, Azarnia N et al.
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Anticancer Drugs 2006;
17: 587-595
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.